New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
09:13 EDTKOOLThermogenesis, TotipotentRX report significant Phase Ib trial results
ThermoGenesis and TotipotentRX announce their co-sponsored Phase Ib clinical trial safety and efficacy results treating no-option patients suffering from critical limb ischemia with Totipotent's Critical Limb Ischemia Rapid Stem cell Therapy, or CLIRST, treatment. The trial achieved both its primary safety and secondary efficacy endpoints at 12 months, achieving statistical significance in five key areas including, major amputation free survival rates, both resting and walking pain reduction, improved walking distance, open wound healing and vasculogenesis in the treated leg. Furthermore, there were no serious adverse events determined to be related to the therapy.
News For KOOL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 8, 2015
07:24 EDTKOOLAegis to hold a conference
Subscribe for More Information
October 7, 2015
07:34 EDTKOOLAlliance for Regenerative Medicine to hold a meeting
Stem Cell Meeting on the Mesa is being held in La Jolla, California on October 7-9.
October 1, 2015
06:10 EDTKOOLCesca Therapeutics partners with St. Jude Children's Research Hospital
Subscribe for More Information
September 28, 2015
16:12 EDTKOOLCesca Therapeutics anounces Kenneth Harris stepping down as president
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use